223 related articles for article (PubMed ID: 25417832)
21. In vitro evaluation of optimized liposomes for delivery of small interfering RNA.
Yang T; Bantegui T; Pike K; Bloom R; Phipps R; Bai S
J Liposome Res; 2014 Dec; 24(4):270-9. PubMed ID: 24708056
[TBL] [Abstract][Full Text] [Related]
22. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
[TBL] [Abstract][Full Text] [Related]
24. Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery.
Podesta JE; Kostarelos K
Methods Enzymol; 2009; 464():343-54. PubMed ID: 19903563
[TBL] [Abstract][Full Text] [Related]
25. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
[TBL] [Abstract][Full Text] [Related]
26. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
27. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
28. Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Forouzanfar T; Helder MN; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):684-692. PubMed ID: 29475393
[TBL] [Abstract][Full Text] [Related]
29. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
[TBL] [Abstract][Full Text] [Related]
30. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J
Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128
[TBL] [Abstract][Full Text] [Related]
31. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
32. Efficient RNA delivery by integrin-targeted glutathione responsive polyethyleneimine capped gold nanorods.
Wang F; Zhang W; Shen Y; Huang Q; Zhou D; Guo S
Acta Biomater; 2015 Sep; 23():136-146. PubMed ID: 26026304
[TBL] [Abstract][Full Text] [Related]
33. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.
Gao J; Yu Y; Zhang Y; Song J; Chen H; Li W; Qian W; Deng L; Kou G; Chen J; Guo Y
Biomaterials; 2012 Jan; 33(1):270-82. PubMed ID: 21963149
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2007 Nov; 6(11):3019-27. PubMed ID: 18025286
[TBL] [Abstract][Full Text] [Related]
35. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
[TBL] [Abstract][Full Text] [Related]
36. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene.
Zhang C; Tang N; Liu X; Liang W; Xu W; Torchilin VP
J Control Release; 2006 May; 112(2):229-39. PubMed ID: 16545478
[TBL] [Abstract][Full Text] [Related]
37. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
38. Molecular medicine for the brain: silencing of disease genes with RNA interference.
Davidson BL; Paulson HL
Lancet Neurol; 2004 Mar; 3(3):145-9. PubMed ID: 14980529
[TBL] [Abstract][Full Text] [Related]
39. EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
Kawashima R; Abei M; Fukuda K; Nakamura K; Murata T; Wakayama M; Seo E; Hasegawa N; Mizuguchi H; Obata Y; Hyodo I; Hamada H; Yokoyama KK
Int J Cancer; 2011 Sep; 129(5):1244-53. PubMed ID: 21710497
[TBL] [Abstract][Full Text] [Related]
40. Lipodendriplexes: A promising nanocarrier for enhanced gene delivery with minimal cytotoxicity.
Tariq I; Pinnapireddy SR; Duse L; Ali MY; Ali S; Amin MU; Goergen N; Jedelská J; Schäfer J; Bakowsky U
Eur J Pharm Biopharm; 2019 Feb; 135():72-82. PubMed ID: 30590107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
